Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios

UK HTA Body Has Issued A Preliminary Rejection Of Breast Cancer Drug For Routine Use

 
• By Neena Brizmohun
  
Coins
NICE says Verzenios is not cost-effective for previously treated breast cancer patients • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access